Boston Scientific (NYSE:BSX) will have a transition at the top of its Cardiac Rhythm Management & Diagnostics (CRMDx) business in 2026.
Zacks Investment Research on MSN
Boston Scientific (BSX) beats stock market upswing: What investors need to know
Boston Scientific (BSX) closed the most recent trading day at $97.79, moving +2.42% from the previous trading session. This change outpaced the S&P 500's 0.62% gain on the day. On the other hand, the ...
Evercore ISI lowered the firm’s price target on Boston Scientific (BSX) to $112 from $113 and keeps an Outperform rating on the shares. Recovering ...
Boston Scientific (NYSE: BSX) has more than doubled in value since early January 2021 – jumping from levels of $36 then to around $82 now – vs. an increase of about 45% for the S&P 500 over this ...
Boston Scientific is a Buy with a $109 target and 14% upside from strong demand, Q3 beats, raised FY25 guidance, and growth ...
If you are like many investors trying to decide whether Boston Scientific belongs in your portfolio right now, you are not alone. There is plenty of buzz swirling around medtech stocks this year, but ...
Stryker has made a quiet offer to acquire its rival Boston Scientific, which would create a behemoth with $21.5 billion in annual sales through one of the largest medical device deals on record, ...
Boston Scientific’s shopping spree for smaller medical-device companies continued on Wednesday when the Marlborough-based company completed its $1.1 billion acquisition of an Israeli surgical laser ...
Sanjeev Valentine, director of Maidax Scientific, put it best in his recent LinkedIn post: Boston Scientific isn't slowing down; it's buying the future of medtech. In ...
Boston Scientific Corporation is rated a Hold with double-digit revenue growth and margin expansion. Learn more about BSX ...
Boston Scientific announced Wednesday that it is acquiring Cosman Medical, which makes radiofrequency ablation systems to treat chronic pain, for an undisclosed sum. The Burlington, Massachusetts, ...
Boston Scientific (NYSE: BSX) spent $2.9 billion on selling, general & administrative (SG&A) expense in 2016, and the figure increased to $3.6 billion in 2018, driven by the growth in sales, and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results